rilotumumab
Small moleculeexperimental
Rilotumumab is a human monoclonal antibody designed for the treatment of solid tumors. — Wikipedia
Clinical trial activity
16 trials · 31 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
13
Phase 3
4
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00427440)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- Hamartoma · Phase 2
- Lung Neoplasms · Phase 2/Phase 3
- Mesothelioma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Proto-Oncogene Proteins c-met · Phase 2/Phase 3
- Rectal Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 3
Mechanism of action
- Hepatocyte growth factorINHIBITOR
HGF inhibitor
In November 2014, Amgen halted all clinical studies of its compound rilotumumab (formerly AMG 102) in advanced gastric cancer.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRilotumumab ↗
- ChEMBLCHEMBL1743063 ↗
Also known as
- amg102
- amg 102
- amg 102
- amg 102
- amg-102
- amg-102
- rilotumumab
- rilotumumab
- rilotumumab
- rilotumumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02137343 | Phase 3 | Jul 1, 2014 | Amgen |
| NCT02926638 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2014 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT02154490 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2014 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT01791374 | Phase 1 | Nov 1, 2012 | Amgen |
| NCT01697072 | Phase 3 | Oct 1, 2012 | Amgen |
| NCT01233687 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Amgen, University of Pittsburgh |
| NCT01443065 | Phase 2 | Jan 1, 2011 | Aix-University of Marseille, Centre Georges Francois Leclerc, Centre Hospitalier La Source, Orleans, Centre Leon Berard, CHR Annecy, CHU Besançon, CHU Morvan, Curie Institute, Groupe Hospitalier Paris Saint Joseph, Institut de Cancerologie de l'Ouest Paul Papin, Institut Gustave Roussy, Institut Paoli-Calmettes, UNICANCER, University of Angers, University of Bordeaux, University of Caen-Normandie, University of Lille, University of Lorraine, University of Lyon, University of Montpellier, University of Nice Sophia Antipolis |
| NCT01039207 | Phase 2 | Oct 1, 2010 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT01113398 | Phase 2 | Aug 1, 2010 | Amgen, Duke University, London Vaccination Clinic |
| NCT01105390 | Phase 2 | Apr 1, 2010 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) |
| NCT00719550 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | Amgen |
| NCT00791154 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2008 | Amgen, NantCell, Inc. |
| NCT00770848 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2008 | Amgen |
| NCT00788957 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2008 | Amgen |
| NCT00422019 | Phase 2 | Jan 1, 2007 | Amgen |
| NCT00427440 | Phase 2 | Nov 1, 2006 | Amgen |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (31)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 11 | 8 | 3 | 2006 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 2 | 2010 |
| Southwest Oncology Group | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Aix-University of Marseille | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Centre Georges Francois Leclerc | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Centre Hospitalier La Source, Orleans | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Centre Leon Berard | Academic/Hospital | 1 | 0 | 1 | 2011 |
| CHR Annecy | Academic/Hospital | 1 | 0 | 1 | 2011 |
| CHU Besançon | Academic/Hospital | 1 | 0 | 1 | 2011 |
| CHU Morvan | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Groupe Hospitalier Paris Saint Joseph | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 0 | 1 | 2011 |
| London Vaccination Clinic | Academic/Hospital | 1 | 1 | 1 | 2010 |
| NantCell, Inc. | For profit | 1 | 1 | 1 | 2008 |
31 organizations
Page 1 / 2